Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 34Leukemia 15Gastrointestinal Stromal Tumors 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Leukemia, Myeloid, Chronic-Phase 7Philadelphia Chromosome 4Leukemia, Myeloid 4Bone Marrow Diseases 4Neoplasms 3Myeloproliferative Disorders 3Hematologic Diseases 3Melanoma 2Hematologic Neoplasms 2Bronchiolitis Obliterans Syndrome 2Blast Crisis 2Synovitis, Pigmented Villonodular 1Recurrence 1Piebaldism 1Peritoneal Neoplasms 1Ovarian Neoplasms 1Neurofibromatoses 1Neurofibroma, Plexiform 1Neurofibroma 1Neoplastic Processes 1Neoplasms by Histologic Type 1Neoplasm Metastasis 1Mastocytosis, Systemic 1Leukemia, Myeloid, Accelerated Phase 1Hypereosinophilic Syndrome 1Glioma 1

Interventions

Taxes 2Standard of Care 2Practice Guidelines as Topic 2Paclitaxel 2palbociclib 1nilotinib 1Telemedicine 1Rifaximin 1Radiation Dose Hypofractionation 1Letrozole 1Interviews as Topic 1Hydroxychloroquine 1Early Intervention, Educational 1Docetaxel 1Acupuncture Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Anatomic Stage I Breast Cancer AJCC v8 × nilotinib × Clear all
NCT04205903 2025-06-29

Nilotinib in Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients With Stage I-III Breast Cancer

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
11 enrolled 9 charts
Breast

Anatomic Stage I Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡